David Molina

Learn More
BACKGROUND Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. Currently, there are no biomarkers allowing to discriminate responders from non-responders before the start(More)
PURPOSE Tumor heterogeneity in medical imaging is a current research trend due to its potential relationship with tumor malignancy. The aim of this study is to analyze the effect of dynamic range and matrix size changes on the results of different heterogeneity measures. MATERIALS AND METHODS Four patients harboring three glioblastomas and one metastasis(More)
  • 1